Castor Appoints Dr. Ben Cons as Chairman of the Supervisory Board

Expansion of Supervisory Board Supports Global Growth Strategy

Amsterdam, Netherlands and Hoboken, New Jersey:  January 8, 2020: Castor, a health-tech company that aims to leverage machine readable data to increase clinical trial efficiency, announced the appointment of Ben Cons, PhD as Chairman of its Supervisory Board. Dr. Cons joins an existing Board of seasoned executives and specialist investors.

Dr. Cons has more than 30 years’ experience in pharmaceutical R&D and commercialization in the biotech, pharmaceutical and financing sectors. A prominent leader in global healthcare and technology, Dr. Cons has 20 years of experience with the NYSE-listed pharmaceutical services company IQVIA and its associated investment fund NovaQuest. Currently, Dr. Cons is a Special Partner at the private equity fund Vitruvian, and a NED at Talking Medicines Ltd, Fluidic Analytics Ltd, and Immune Regulation Ltd. He is also an investment member of private capital group, 24Haymarket and an investment panel member at Future Care Capital, a charity focusing on future health and social care policy.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...